Brief Summary of Prescribing Information for XARELTO® (rivaroxaban)
XARELTO® (rivaroxaban) tablets, for oral use
See package insert for full Prescribing Information
XARELTO® (rivaroxaban) tablets
To reduce the potential risk of bleeding associated with the concurrent
use of rivaroxaban and epidural or spinal anesthesia/analgesia or spinal
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO
puncture, consider the pharmacokinetic profile of rivaroxaban [see
INCREASES THE RISK OF THROMBOTIC EVENTS,
Clinical Pharmacology (12.3) in full Prescribing Information]. Placement
(B) SPINAL/EPIDURAL HEMATOMA
or removal of an epidural catheter or lumbar puncture is best performed
A. PREMATURE DISCONTINUATION OF XARELTO INCREASES THE
when the anticoagulant effect of rivaroxaban is low; however, the exact
RISK OF THROMBOTIC EVENTS
timing to reach a sufficiently low anticoagulant effect in V6